Compounds > imm-h004
Page last updated: 2024-11-13

imm-h004

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

IMM-H004: Neuroprotective Agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72375487
CHEMBL ID2419402
MeSH IDM0594268

Synonyms (7)

Synonym
CHEMBL2419402
imm-h004
AKOS025396059
1456807-80-9
7-hydroxy-5-methoxy-4-methyl-3-(4-methylpiperazin-1-yl)-2h-chromen-2-one
2h-1-benzopyran-2-one, 7-hydroxy-5-methoxy-4-methyl-3-(4-methyl-1-piperazinyl)-
7-hydroxy-5-methoxy-4-methyl-3-(4-methyl piperazin-1-yl)-coumarin

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The results of this study lend further credence to the notion that IMM-H004 is a 'multipotent therapeutic agrent' that reduces toxic levels of brain Aβ, and holds the potential to protect neuronal mitochondrial function in Alzheimer's disease."( IMM-H004, a novel coumarin derivative compound, protects against amyloid beta-induced neurotoxicity through a mitochondrial-dependent pathway.
Chen, NH; Han, N; Hu, JF; Ji, HJ; Li, ZP; Liu, G; Song, XY; Sun, MN; Wu, DH; Yuan, YH; Zhu, ZX, 2013)		2.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID768364Cmax in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv measured at 2 mins by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768378In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as reduction of brain-water content at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768379In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as reduction of infarct size at 6 mg/kg, iv measured 24 hrs post reperfusion by TTC staining assay relative to vehicle-treated control2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768374In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuronal loss in hippocampus at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by TUNEL assay2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768376In vivo neuroprotective activity in iv dosed Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuronal loss in hippocampus measured 24 hrs post reperfusion by nissl staining assay2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768371Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as upregulation of Bcl-2 protein expression in hippocampus at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis relative to v2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768380In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as reduction of infarct size at 3 mg/kg, iv measured 24 hrs post reperfusion by TTC staining assay relative to vehicle-treated control2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768357Volume of distribution in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768361Terminal half life in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768352Drug uptake in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv measured at 60 mins by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768353Drug uptake in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv measured at 60 mins by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768359AUC in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768363Tmax in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768375In vivo neuroprotective activity in iv dosed Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuronal loss in cerebral cortex measured 24 hrs post reperfusion by nissl staining assay2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768358AUC in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768373In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuronal loss in cerebral cortex at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by TUNEL assay2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768355Clearance in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768360Terminal half life in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768362Tmax in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768383Cytotoxicity against rat PC12 cells assessed as cell proliferation at 10 uM by MTT assay relative to control2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768354Clearance in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768381In vivo neuroprotective activity in iv dosed Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as reduction of infarct size measured 24 hrs post reperfusion by TTC staining assay2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768365Cmax in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv measured at 2 mins by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768369Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as inhibition of Bax protein expression in hippocampus at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis relative to vehic2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768366Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as inhibition of cleaved caspase-3 protein expression in cerebral cortex at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768356Volume of distribution in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768372In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuropathological changes at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by uranyl acetate/lead citrate staining-bas2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768382Neuroprotective activity in rat PC12 cells assessed as attenuation of oxygen-glucose deprivation-induced cellular damage at 10 uM by MTT assay relative to control2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768368Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as inhibition of Bax protein expression in cerebral cortex at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis relative to v2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768367Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as inhibition of cleaved caspase-3 protein expression in hippocampus at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis rel2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
AID768370Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as upregulation of Bcl-2 protein expression in cerebral cortex at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis relative 2013European journal of medicinal chemistry, Sep, Volume: 67Coumarin derivatives protect against ischemic brain injury in rats.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.74 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
antipyrine
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.		2.1110pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
edaravone
[no description available]		2.520pyrazoloneantioxidant;
radical scavenger
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.0810
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		4.15140benzenes;
hydroxycoumarin;
methyl ketone
okadaic acid
Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.		2.5720ketal
ConditionIndicatedRelationship StrengthStudiesTrials
Cerebral Ischemia
[description not available]		03.2350
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		03.2350
Acute Confusional Senile Dementia
[description not available]		02.2110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.0540
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.2110
Cerebral Infarction, Middle Cerebral Artery
[description not available]		02.5220
Brain Swelling
[description not available]		02.1510
Injury, Ischemia-Reperfusion
[description not available]		02.8630
Brain Edema
Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)		02.1510
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		07.8630
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		02.5220
Apoplexy
[description not available]		02.2110
Acute Brain Injuries
[description not available]		02.6120
Innate Inflammatory Response
[description not available]		02.5420
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.2110
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		02.6120
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		07.5420
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		02.2110
Brain Hemorrhage, Cerebral
[description not available]		02.110
Cerebral Hemorrhage
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.		02.110
Thromboembolism
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.		02.110
Academic Disorder, Developmental
[description not available]		02.1110
Learning Disabilities
Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.		02.1110
Anterior Circulation Transient Ischemic Attack
[description not available]		02.1510
Ischemic Attack, Transient
Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)		02.1510
Age-Related Memory Disorders
[description not available]		02.1310
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.1310